 "Aurobindo Pharma, Glenmark Pharma hit 52-week highs")
Shares of Aurobindo Pharma and Glenmark Pharmaceuticals from the pharma sector hit their respective 52-week highs on the BSE in intra-day trade on Friday.
At 10:23 am; the S&P BSE Sensex was trading 0.04% lower at 38,227 points, after hitting an intra-day low of 38,067 today.
Aurobindo Pharma was up 9% at Rs 826, surging 22% in the past three trading days after the company on Thursday announced the acquisition of Sandoz’s generic business in the US for $900 million. Currently US business contributes to around 45% of its revenue.
“Sandoz acquisition seems to be transacted at attractive valuations (1x sales and 5x EBITDA), which will give Aurobindo higher scale (USD 2.3bn of consolidated US sales) and diversification in US (derma portfolio). Although the generics cycle in the US is going through a tough environment, we see Sandoz acquisition as value-accretive,” analysts at Elara Capital said in event update.
“Strong US business and an emerging EU (transitioning from negative OPM into the double digits) show drivers are in place. The EIR receipt for Unit IV in April 2018 and gErtapenem launch will aid in injectables sales in the US in FY19,” the brokerage firm said with a ‘buy’ rating on the stock and target price of Rs 836 per share.
Glenmark Pharma was up 2% at Rs 692, gaining 8% in past eight trading days after the company on August 29, entered into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler (DPI) in Western Europe.
Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD). According to data from IQVIA, Boehringer Ingelheim’s Spiriva Handihaler recorded sales of US $724 million in the EU in the 12 month period ended March 2018.
At 10:23 am; the S&P BSE Sensex was trading 0.04% lower at 38,227 points, after hitting an intra-day low of 38,067 today.
Aurobindo Pharma was up 9% at Rs 826, surging 22% in the past three trading days after the company on Thursday announced the acquisition of Sandoz’s generic business in the US for $900 million. Currently US business contributes to around 45% of its revenue.
“Sandoz acquisition seems to be transacted at attractive valuations (1x sales and 5x EBITDA), which will give Aurobindo higher scale (USD 2.3bn of consolidated US sales) and diversification in US (derma portfolio). Although the generics cycle in the US is going through a tough environment, we see Sandoz acquisition as value-accretive,” analysts at Elara Capital said in event update.
“Strong US business and an emerging EU (transitioning from negative OPM into the double digits) show drivers are in place. The EIR receipt for Unit IV in April 2018 and gErtapenem launch will aid in injectables sales in the US in FY19,” the brokerage firm said with a ‘buy’ rating on the stock and target price of Rs 836 per share.
Glenmark Pharma was up 2% at Rs 692, gaining 8% in past eight trading days after the company on August 29, entered into an exclusive licensing agreement to commercialize generic Tiotropium Bromide dry powder inhaler (DPI) in Western Europe.
Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD). According to data from IQVIA, Boehringer Ingelheim’s Spiriva Handihaler recorded sales of US $724 million in the EU in the 12 month period ended March 2018.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%